Advertisement
Marking a path to transplant tolerance
Vicki Seyfert-Margolis and Laurence A. Turka
Find articles by Seyfert-Margolis, V. in: JCI | PubMed | Google Scholar
Find articles by Turka, L. in: JCI | PubMed | Google Scholar
Published September 2, 2008 - More info
J Clin Invest. 2008;118(9):3240–3240. https://doi.org/10.1172/JCI36552E1.
© 2008 The American Society for Clinical Investigation
Related article:
Abstract
Long-term allograft survival requires lifelong immunosuppression, which comes with serious side effects. Inducing immune tolerance to the transplant would enable immunosuppression withdrawal and revolutionize the quality of life of transplant recipients. In this issue of the JCI, Martínez-Llordella et al. identify a profile of biomarkers that predict tolerance in liver transplant recipients (see the related article beginning on page 2845). These findings translate into a new means for prospectively selecting liver transplant patients who would benefit from immunosuppression withdrawal and ultimately may guide development of tolerogenic therapies that allow for allograft acceptance without the use of long-term immunosuppression.
Authors
Vicki Seyfert-Margolis, Laurence A. Turka
Original citation: J. Clin. Invest.118:2684–2686 (2008). doi:10.1172/JCI36552.
Citation for this erratum: J. Clin. Invest.118:3240 (2008). doi:10.1172/JCI36552E1.
During the preparation of the manuscript, δ1-γδTCR+ was mistyped as δa-γδTCR+ in the section “Can we predict tolerance?” on page 2684. The error has since been corrected online.
The JCI regrets the error.
Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)